副主任药师/副研究员 医学博士（硕士生导师）
上海交通大学医学院附属第一人民医院临床药学科主任助理

教育经历：
2011/09-2015/09，上海交通大学，药学，博士
2004/09-2007/07，哈尔滨医科大学yd12300云顶线路，药理学，硕士
1999/09-2004/07，山西医科大学，临床医学，学士

科研与学术工作经历：
2020/5-至今，上海交通大学医学院附属第一人民医院，副主任药师/副研究员
2017/12-2020/5，上海交通大学，副研究员
2010/01－2017/12，上海交通大学，助理研究员
2007/08－2009/12，上海交通大学，研究实习员

主要学术兼职：
担任上海市药学会药物分析专委会 委员（秘书）；中国医药教育协会老年药学专业委员会委员；中国药理学会专业委员会委员；上海市药理学会TDM专委会青年委员；中国老年保健协会药品和器械合理使用与风险评估分会青年委员；《中国药房》青年编委；JCM杂志客座编辑。

1. 临床药学转化研究
2. 中药临床前研究
3. 中药分子药理学和多组学研究

代表性论文：
1. Huang, S., Z. Wu, B. Zhou, et al., Heat-Denatured Lysozyme is a Novel Potential Non-alcoholic Disinfectant Against Respiratory Virus. Food and Environmental Virology, 2023.
2. Qu, H., J. Wu, C. Ma, et al., Safety Profile of Eltrombopag in Different Age Groups: An Analysis of Real-World Pharmacovigilance and Randomized Clinical Trials. Clin Pharmacol Ther, 2023.
3. Zhao, Y., C. Ma, Q. Qiu, et al., Exploring the components and mechanisms of Shen-qi-wang-mo granule in the treatment of retinal vein occlusion by UPLC-Triple TOF MS/MS and network pharmacology. Sci Rep, 2023. 13(1): p. 5330.
4. Qiaolongbatu, X., W. Zhao, X. Huang, et al., The Therapeutic Mechanism of Schisandrol A and Its Metabolites on Pulmonary Fibrosis Based on Plasma Metabonomics and Network Analysis. Drug Des Devel Ther, 2023. 17: p. 477-496.
5. Jia, M., Z. Wu, W. Shi, et al., Simultaneous online SPE-HPLC-MS/MS quantification of gefitinib, osimertinib and icotinib in dried plasma spots: Application to therapeutic drug monitoring in patients with non-small cell lung cancer. Journal of Pharmaceutical and Biomedical Analysis, 2023: p. 115275.
6. Shi, W., Z. Wu, J. Wu, et al., A comprehensive quality control evaluation for standard decoction of Smilax glabra Roxb based on HPLC-MS-UV/CAD methods combined with chemometrics analysis and network pharmacology. Food Chem, 2023. 410: p. 135371.
7. Liu, Y., M. Jia, A. Gao, et al., Attenuation of Liver Injury via Bicyclol–Bovine Serum Albumin Nanopreparation using a Green Synthetic Approach. Journal of Nanomaterials, 2022. 2022: p. 7740768.
8. Huang, X., M. Jia, Y. Liu, Z. Wu*, Y. Lou*, G. Fan*,, Identification of bicyclol metabolites in rat plasma, urine and feces by UPLC-Q-TOF-MS/MS and evaluation of the efficacy and safety of these metabolites based on network pharmacology and molecular docking combined with toxicity prediction. J Pharm Biomed Anal, 2022. 220: p. 114947.
9. Ma, C., Z. Wu, X. Wang, et al., A systematic comparison of anti-angiogenesis efficacy and cardiotoxicity of receptor tyrosine kinase inhibitors in zebrafish model. Toxicol Appl Pharmacol, 2022. 450: p. 116162.
10. Wu, Z., M. Jia, W. Zhao, et al., Schisandrol A, the main active ingredient of Schisandrae Chinensis Fructus, inhibits pulmonary fibrosis through suppression of the TGF-beta signaling pathway as revealed by UPLC-Q-TOF/MS, network pharmacology and experimental verification. J Ethnopharmacol, 2022. 289: p. 115031.
11. L. Zhou, S. Wang, M. Chen, S. Huang, M. Zhang, W. Bao, A. Bao, P. Zhang, H. Guo, Z. Liu, G. Xie, J. Gao, Z. Wu*, Y. Lou*, G. Fan*, Simultaneous and rapid determination of 12 tyrosine kinase inhibitors by LC-MS/MS in human plasma: Application to therapeutic drug monitoring in patients with non-small cell lung cancer, J Chromatogr B Analyt Technol Biomed Life Sci 1175 (2021) 122752.
12. Hema Negi ; Siva Bharath Merugu ; Hitesh Bhagavanbhai Mangukiya; Zheqi Li; Bingjie Zhou; Qudsia Sehar; Suchitra Kamle; Fakhar-un-Nisa Yunus; Dhahiri Saidi Mashausi; Zhenghua Wu; Dawei Li , Anterior Gradient-2 Monoclonal Antibody Inhibits Lung Cancer Growth and Metastasis by Upregulating p53 Pathway and Without Exerting Any Toxicological Effects: A Preclinical Study，Cancer Letters, 2019，449，125-134. (2019.5.1).
13. Hitesh Bhagavanbhai Mangukiya, Hema Negi, Siva Bharath Merugu, Qudsia Sehar, Dhahiri Saidi Mashausi, Fakhar-Un-Nisa Yunus, Zhenghua Wu, Dawei Li. Paracrine signalling of AGR2 stimulates RhoA function in fibroblasts and modulates cell elongation and migration. Cell Adhesion & Migration. 2019, VOL. 13, NO. 1, 332–344.
14. Sehar Qudsia; Siva B. Merugu; Hitesh B. Mangukiya; Negi Hema，Zhenghua Wu, Dawei Li，A novel lentiviral scFv display library for rapid optimization and selection of high affinity antibodies, Biochemical and Biophysical Research Communications, 2018.4.30, 499(1): 71~77.
15. H Guo, Q Zhu, X Yu, S B Merugu, H B Mangukiy, N Smith4, Z Li, B Zhang, H Negi, R Rong, K Cheng, Z Wu and D Li, Tumor-secreted anterior gradient-2 binds to VEGF and FGF2 and enhances their activities by promoting their homodimerization. Oncogene, 2017.9.7, 36(36): 5098~5190.
16. Zhu Q, Mangukiya HB, Mashausi DS, Guo H, Negi H, Merugu SB, Wu Z, Li D. Anterior Gradient 2 (AGR2) is induced in cutaneous wound and promotes wound healing through its adhesion domain. FEBS J. 2017.7.1, 284(17), 2856-2869.
17. Zheqi Li, Qi Zhu1, Lingyun Hu, Hao Chen1, Hema Negi, Zhenghua Wu, Dawei Li, Binding of anterior gradient 2 and estrogen receptor-α: dual critical roles in enhancing fulvestrant resistance and IGF-1-induced tumorigenesis of breast cancer. Cancer letter, 2016.4.12, 377(1): 32-43.
18. Zhenghua Wu, Kebin Cheng, Lidan Shi, Zheqi Li, Hema Negi, Guangwei Gao, Suchitra Kamle, Dawei Li，Sal-like protein 2 upregulates p16 expression through a proximal promoter element, Cancer Science, 2015, 106(3): 253-261.
19. Zheqi Li, Zhenghua Wu, Hao Chen, Qi Zhu, Guangwei Gao, Lingyun Hu, Hema Negi, Suchitra Kamle and Dawei Li，Induction of anterior gradient2 (AGR2) plays a key role in insulin-like growth factor-1 (IGF-1)-induced breast cancer cell proliferation and migration, Medical Oncology, 2015.5.10, 32(6)：577-588.
20. Zheqi Li, Lingyun Hu, Hao Chen, Qi Zhu, Zhenghua Wu and Dawei Li, Anterior gradient 2 is a binding stabilizer of HIF-1α that enhances CoCl2-induced doxorubicin resistance in breast cancer cells, Cancer Science, 2015.6.17, 106(8): 1041-1049.

主持国家自然科学基金、上海市 “科技创新行动计划”生物医药科技支撑专项项目、白求恩·求索-药学科研能力建设项目、吴阶平医学基金会临床科研专项资助基金，松江区科技攻关项目等多个科研项目；获国内、国际授权专利5项；以通讯或第一作者在SCI期刊上发表论文近20篇。
获得日本癌症协会Cancer Science Young Scientists Award、浦江DMPK论坛优秀奖、上海药学会临床药学分会优秀成果奖，上海药理学会年会优秀成果奖、上海市药学会论文一等奖等。